Michael Higgins • Ladenburg Thalmann & Co. Inc.

Michael Higgins is Managing Director, Equity Research at Ladenburg Thalmann & Co. Inc., specializing in healthcare with a focus on biopharmaceuticals. He covers companies such as SCYNEXIS, Zynerba Pharmaceuticals, and other healthcare firms, and his analyst record includes coverage of 44 stocks, a 30% success rate on recommendations, and an average return per transaction of -1.8%. Joining Ladenburg Thalmann in 2018 after serving as Managing Director and Senior Research Analyst at ROTH Capital Partners and Rodman & Renshaw, Higgins previously began his equity research career at Dafna Capital, building on a decade in pharmaceutical marketing at Procter & Gamble. He holds a BS in Finance from the University of Wisconsin-Stevens Point and an MBA with a focus on Finance and Investment Analysis from Marquette University.